该词条未找到_海词词典

您要查找的是不是：

Rho kinase inhibitors Rho激酶抑制剂
Rho kinase inhibitor Rho激酶抑制剂
Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer? PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用?
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors are reviewed. 综述了EGFR的结构和作用以及近年来EGFR酪氨酸激酶抑制剂的研究进展。
Volatile anesthetic agents such as halothane,isoflurane,sevoflurane have demon- strated to attenuate [Ca~(2+)] i and inhibit activation of PKC,Rho kinase and p44/42 MAPK of VSM. Volatile anesthetics also depress release of EDRFs and open K_(ATP)channel. 吸入性麻醉药如氟烷、异氟醚、七氟醚等被证明通过抑制平滑肌[Ca~(2+)]i升高和PKC、Rho激酶、p44/42 MAPK的活性、同时也通过抑制EDRFs的释放和增加K_(ATP)通道的开放来扩张血管。
Genistein, the tyrosine kinase inhibitors, plays the effect by an inhibiton of tyrosine phosphorlation. Genistein是酪氨酸激酶的非特异性抑制剂，通过抑制酪氨酸的磷酸化而发挥作用。
The progress in tyrosine kinase inhibitor has been reviewed, including the chemical structures and the pharmacophore models. 本文综述了近年来酪氨酸激酶抑制剂的研究进展，包括抑制剂的结构和与激酶作用的药效团模型。
Electively targeting of signaling pathways using protein kinase inhibitors would have a potential advantage over receptor blockers. 这种用来选择性地阻断信号转导途径的蛋白激酶抑制剂可能是一种潜在的有利的受体阻断剂。
Response rates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in cancer treatment have been surprisingly and disappointingly low. EGFR酪氨酸激酶抑制剂在肿瘤的治疗中的反应率是出乎意料和令人失望的低。
And PI3 kinase inhibitor LY294002 blocked the differentiation of ADAS cells into endothelial cells in vitro. 利用信号通路特异性抑制剂抑制实验，提示PI3K在ADAS细胞向内皮细胞分化中
The effect of different cag pathogenicity island and various kinase inhibitors on Helicobacter pylori induced interleukin-8 secretion in gastric epithelial cells. cag致病岛的差异及不同激酶抑制剂对幽门螺杆菌诱导胃上皮细胞IL-8分泌的影响
We detected the T790M mutation, which confers drug resistance, in circulating tumor cells collected from patients with EGFR mutations who had received tyrosine kinase inhibitors. 在从接受酪氨酸激酶抑制剂治疗患者中收集的循环肿瘤细胞中，我们检测到了引起耐药的T790M突变，
A 3D database searching was conducted with 3DFS in 3D database using the pharmacophore of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 摘要用表皮生长因子受体酪氨酸激酶抑制剂的药效团作为提问结构在三维数据库中进行了搜索。
Objective To build 3D-pharmacophore model of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors using distance comparisons method and design novel EGFR inhibitors. 目的构建表皮生长因子受体(EGFR)抑制剂的药效团模型,设计新结构类型的化合物。
Gefitinib, the first EGFR tyrosine kinase inhibitor put into clinical trial, was put into market in Japan in 2002. 吉非替尼是EGFR酪氨酸激酶抑制剂中最早进入临床试验的口服药物，2002年首次于日本上市。
EGFR tyrosine kinase inhibitor is an investigative hot spot in targeted therapy of non-small cell lung cancer (NSCLC). 摘要EGFR靶向抑制剂，是目前NSCLC靶向治疗的研究热点之一。
Gefitinib (Iressa, ZD1839), a specific tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), is a novel molecular-targeting antineoplastic agent. 摘要吉非替尼是一种新型的分子靶向抗癌药物，它选择性抑制表皮生长因子受体酪氨酸激酶而发挥作用。
Objective To assess the effect of tyrosine kinase inhibitor (2,5-MC) on the inhibition of in-stent inti-mal hyperplasia. 目的评估酪氨酸蛋白激酶抑制剂2,5-MC抑制支架植入术后内膜增殖的效果。